OOIR: Observatory of International Research

Papers

(The TQCC of Clinical Microbiology Reviews is 34. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
2025 Acknowledgment of CMR Reviewers	244
Extracutaneous sporotrichosis	232
Wild-type distributions of minimum inhibitory concentrations and epidemiological cut-off values—laboratory and clinical utility	181
Vaccines and monoclonal antibodies to prevent healthcare-associated bacterial infections	178
Integrating whole-genome sequencing into antimicrobial resistance surveillance: methodologies, challenges, and perspectives	147
Erratum for Nyaruaba et al., “Digital PCR Applications in the SARS-CoV-2/COVID-19 Era: a Roadmap for Future Outbreaks”	136
Antibiotic tolerance among clinical isolates: mechanisms, detection, prevalence, and significance	121
The long reach of influenza and other respiratory viruses: from acute epithelial injury to post-viral lung disease	121
The sex hormone-gut microbiome axis: mechanistic drivers of sex-disparate bacterial infection outcomes and precision clinical interventions	115
Viral infections and pathogenesis of glaucoma: a comprehensive review	108
Progression of antibiotic resistance in Neisseria meningitidis	105
Sensitivity to Vaccines, Therapeutic Antibodies, and Viral Entry Inhibitors and Advances To Counter the SARS-CoV-2 Omicron Variant	99
Emerging hybrid shigatoxigenic and enteropathogenic Escherichia coli serotype O80:H2 in humans and calves	98
Mechanisms of microbial colonization in biofilm-associated infections of hemodialysis catheters and advances in surface modification technologies	93
HIV-associated cancers and lymphoproliferative disorders caused by Kaposi sarcoma herpesvirus and Epstein-Barr virus	90
Clostridioides difficile infection: history, epidemiology, risk factors, prevention, clinical manifestations, treatment, and future options	89
Intestinal biofilms: pathophysiological relevance, host defense, and therapeutic opportunities	86
A review of post-exposure strategies for high-consequence viral pathogens in the laboratory	85
Decontamination approaches and strategies for the prevention of sink drain-related healthcare-associated infections	83
Canonical fact versus hypothesis testing to decipher transmission of non-tuberculous and tuberculous mycobacteria: a comparative review	78
Review of BCG immunotherapy for bladder cancer	77
Non- faecium non- faecalis enterococci: a review of clinical manifestations, virulence factors, and antimicrobial resistance	75
Extrapolation and comparison of West Nile virus- and Usutu virus-associated neurological diseases in humans: linking pathology to clinical symptoms	74
Henipaviruses: epidemiology, ecology, disease, and the development of vaccines and therapeutics	74
Neisseria gonorrhoeae vaccines: a contemporary overview	70

Drug-resistant Acinetobacter baumannii : mortality, emerging treatments, and future pharmacological targets for a WHO priority pathogen	67
Clonorchiasis and opisthorchiasis: epidemiology, transmission, clinical features, morbidity, diagnosis, treatment, and control	66
Congenital Syphilis: a Review of Global Epidemiology	64
Erratum for Cho et al., “Recent advances in therapeutic probiotics: insights from human trials”	62
Bacterial and fungal infections in persons who inject drugs	61
An unintended consequence: a review of iatrogenic central nervous system mold infections and outbreaks	59
Serratia species as paratransgenic vehicles: potential applications in vector-borne disease control	58
Fungal diagnostic stewardship in immunocompromised populations: a focus on molds and dimorphic fungi	56
Diagnosis, Management, and Future Control of Cholera	55
Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease	55
The ecological dynamics of skin microbiota in skin health and diseases	51
BCG therapy in bladder cancer and its tumor microenvironment interactions	50
Implementation of pathogen genomics in clinical microbiology laboratories	49
Rapid and accurate testing for urinary tract infection: new clothes for the emperor	44
COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes	42
The mRNA Vaccine Technology Era and the Future Control of Parasitic Infections	41
Harnessing the host response for precision infectious disease diagnosis	40
Mechanistic insights into the pathogenesis and therapeutic recalcitrance of Staphylococcus aureus osteomyelitis	40
Plasmids in Neisseria gonorrhoeae : drivers of DoxyPEP failure and an emerging threat for current therapy	40
Lyme borreliosis in Brazil: a critical review on the Baggio–Yoshinari syndrome (Brazilian Lyme-like disease)	40
Agnostic Sequencing for Detection of Viral Pathogens	38
Immunosuppressant imprecision: multidirectional effects on metabolism and microbiome	38
Convalescent plasma for COVID-19: planning for the next pandemic using the worldwide experience	38
Artemisinin-resistant malaria	35
Editorial Board	34